These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36400667)

  • 1. How hypocretin agonists may improve the quality of wake in narcolepsy.
    Justinussen JL; Egebjerg C; Kornum BR
    Trends Mol Med; 2023 Jan; 29(1):61-69. PubMed ID: 36400667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expert opinion on pharmacotherapy of narcolepsy.
    Zaharna M; Dimitriu A; Guilleminault C
    Expert Opin Pharmacother; 2010 Jul; 11(10):1633-45. PubMed ID: 20426704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions.
    Zeitzer JM; Nishino S; Mignot E
    Trends Pharmacol Sci; 2006 Jul; 27(7):368-74. PubMed ID: 16766052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The sleep-wake cycle, the hypocretin/orexin system and narcolepsy: advances from preclinical research to treatment.
    Arias-Carrión O; Bradbury M
    CNS Neurol Disord Drug Targets; 2009 Aug; 8(4):232-4. PubMed ID: 19689304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hypocretin neurotransmission system in myotonic dystrophy type 1.
    Ciafaloni E; Mignot E; Sansone V; Hilbert JE; Lin L; Lin X; Liu LC; Pigeon WR; Perlis ML; Thornton CA
    Neurology; 2008 Jan; 70(3):226-30. PubMed ID: 18195268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy.
    Ishikawa T; Hara H; Kawano A; Tohyama K; Kajita Y; Miyanohana Y; Koike T; Kimura H
    J Pharmacol Exp Ther; 2023 Jun; 385(3):193-204. PubMed ID: 37001988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Narcolepsy: etiology, clinical features, diagnosis and treatment].
    Zawilska JB; Woldan-Tambor A; Płocka A; Kużajska K; Wojcieszak J
    Postepy Hig Med Dosw (Online); 2012 Oct; 66():771-86. PubMed ID: 23175331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypocretin (orexin) deficiency predicts severe objective excessive daytime sleepiness in narcolepsy with cataplexy.
    Baumann CR; Khatami R; Werth E; Bassetti CL
    J Neurol Neurosurg Psychiatry; 2006 Mar; 77(3):402-4. PubMed ID: 16484654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The present and future of synthetic orexin receptor agonists.
    Saitoh T; Sakurai T
    Peptides; 2023 Sep; 167():171051. PubMed ID: 37422012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy.
    Mishima K; Fujiki N; Yoshida Y; Sakurai T; Honda M; Mignot E; Nishino S
    Sleep; 2008 Aug; 31(8):1119-26. PubMed ID: 18714784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines.
    Hungs M; Fan J; Lin L; Lin X; Maki RA; Mignot E
    Genome Res; 2001 Apr; 11(4):531-9. PubMed ID: 11282968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of measuring CSF hypocretin-1 level in patients with suspected narcolepsy.
    Gabryelska A; Szmyd B; Maschauer EL; Roguski A; Canham R; Morrison I; Białasiewicz P; Riha RL
    Sleep Med; 2020 Jul; 71():48-51. PubMed ID: 32492554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Animal models of narcolepsy and the hypocretin/orexin system: Past, present, and future.
    Tisdale RK; Yamanaka A; Kilduff TS
    Sleep; 2021 Jun; 44(6):. PubMed ID: 33313880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypocretin (orexin) deficiency in narcolepsy and primary hypersomnia.
    Ebrahim IO; Sharief MK; de Lacy S; Semra YK; Howard RS; Kopelman MD; Williams AJ
    J Neurol Neurosurg Psychiatry; 2003 Jan; 74(1):127-30. PubMed ID: 12486284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypocretin administration as a treatment for human narcolepsy.
    Siegel JM
    Sleep; 2003 Dec; 26(8):932-3. PubMed ID: 14746368
    [No Abstract]   [Full Text] [Related]  

  • 16. Narcolepsy: pathophysiology and pharmacology.
    Nishino S
    J Clin Psychiatry; 2007; 68 Suppl 13():9-15. PubMed ID: 18078360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orexin supplementation in narcolepsy treatment: A review.
    Nepovimova E; Janockova J; Misik J; Kubik S; Stuchlik A; Vales K; Korabecny J; Mezeiova E; Dolezal R; Soukup O; Kobrlova T; Pham NL; Nguyen TD; Konecny J; Kuca K
    Med Res Rev; 2019 May; 39(3):961-975. PubMed ID: 30426515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The hypocretin/orexin system in health and disease.
    Nishino S
    Biol Psychiatry; 2003 Jul; 54(2):87-95. PubMed ID: 12873797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the efficacy of the hypocretin/orexin receptor agonists TAK-925 and ARN-776 in narcoleptic orexin/tTA; TetO-DTA mice.
    Sun Y; Ranjan A; Tisdale R; Ma SC; Park S; Haire M; Heu J; Morairty SR; Wang X; Rosenbaum DM; Williams NS; De Brabander JK; Kilduff TS
    J Sleep Res; 2023 Aug; 32(4):e13839. PubMed ID: 36808670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transgenic Archaerhodopsin-3 Expression in Hypocretin/Orexin Neurons Engenders Cellular Dysfunction and Features of Type 2 Narcolepsy.
    Williams RH; Tsunematsu T; Thomas AM; Bogyo K; Yamanaka A; Kilduff TS
    J Neurosci; 2019 Nov; 39(47):9435-9452. PubMed ID: 31628177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.